You have 9 free searches left this month | for more free features.

City

Shanghai (1)

Condition

HER2-positive Advanced Breast Cancer (1)

HER2-positive Advanced Solid Tumors (1)

HER2-positive Breast Cancer (1)

Overall Status

Not yet recruiting (2)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

phase 3 (1)

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (3)

Collaborator

Intervention

dp303c (3)

capecitabine tablets (1)

trastuzumab (1)

vinorelbine tartrate (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (3)

dp303c

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

HER2-positive Advanced Solid Tumors Trial in Shanghai (DP303c)

Recruiting

HER2-positive Advanced Solid Tumors

DP303c

Shanghai, Shanghai, China

Fudan University Shanghai Cancer Center

Apr 10, 2023

HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)

Not yet recruiting

HER2-positive Advanced Breast Cancer

DP303c
+3 more

(no location specified)

Jun 4, 2023

HER2-positive Breast Cancer Trial (DP303c)

Not yet recruiting

HER2-positive Breast Cancer

DP303c

(no location specified)

Apr 13, 2022